The successful targeting of GNR-Man/PRGD towards both MR and αvβ3 integrin receptors resulted in a highly effective PTT for TNBC in vitro and in vivo, evidenced through the nearly complete tumor ablation and no tumor regrowth being observed 15 days after PTT. Here, NR3C2 is linked to neoplasm.